Login to Your Account



Innate Pharma stock drops on mixed DSMB recommendation

By Cormac Sheridan
Staff Writer

Thursday, March 26, 2015

Shares in Innate Pharma SA fell 14 percent Thursday on news that a DSMB called a halt to one treatment arm of a phase II trial in AML testing lirilumab (IPH2102, BMS-986015), an immunotherapeutic antibody that targets inhibitory KIRs expressed by NK cells.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription